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ABSTRACT 
 
Objective: Cognitive and behavioural change in Amyotrophic Lateral Sclerosis (ALS) is well 
accepted. Several screening tools have been developed to detect such changes. Further guidance on 
their use may come from a consideration of the rigour with which they were validated. This 
systematic review set out to critically appraise and present published data pertaining to the validation 
of six screening tools used to diagnose cognitive and/or behavioural change in patients with ALS.  
 
Methods:  The screening tools considered in this search included: The Edinburgh Cognitive and 
Behavioural ALS Screen (ECAS), The ALS Cognitive Behavioural Screen (ALS-CBS), The Motor 
Neurone Disease Behavioural Scale (MiND-B), The Frontal Behavioural Inventory ALS Version, The 
ALS Frontotemporal Dementia Questionnaire (ALS-FTD-Q) and The Beaumont Behavioural 
Inventory (BBI). MEDLINE, EMBASE and PsycINFO were searched until 4th week of June 2017.  
 
Results: Fourteen eligible studies were included in the review. Papers either reported data concerning 
convergent validity or clinical validity. Validation data concerning the ECAS showed this screening 
tool to have strong clinical validity, although further work needs to consider how its use will affect 
diagnosis rates according to current diagnostic guidelines. When screening for behavioural change 
only, more limited information is available; the BBI may offer greater potential than the ALS-FTD-Q 
for detecting mild impairment as it assesses a wider range of behavioural changes.  
 
Conclusions: Scores of sensitivity, specificity, positive predictive values and negative predictive 
values should be given considerable importance when considering which screening tools to 
incorporate into current clinical practice. 
 
Keywords:  
Amyotrophic Lateral Sclerosis; Cognition; Behaviour; Screening tests; Validity.  
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INTRODUCTION 
 
Aside from the clinical signs suggestive of motor deficit revealed on examination, over 50% of 
patients with Amyotrophic Lateral Sclerosis (ALS) present with cognitive difficulties indicative of 
frontotemporal dysfunction (1,2); of these between 8% and 14% may meet criteria for frontotemporal 
dementia (FTD) (1,2). Approximately 35% have a milder form of cognitive involvement, 
characterised by executive and/or language dysfunction and possible deficits in social cognition (3). 
In ALS patients with behavioural involvement, apathy is the most commonly found presentation (seen 
in up to 70 percent of patients (4)); severe apathy tends to lead to a poorer prognosis (4). ALS patients 
may also show signs of disinhibition, reduced empathy and increased egocentric behaviour, a change 
in dietary habits and more stereotyped behaviour (4).  
 
Although it is optimal for patients with ALS to undergo detailed neuropsychological assessments to 
identify and characterise cognitive and behavioural changes, sufficient clinical resources are not 
always available (5). Further, it may be inappropriate to subject all patients to a full 
neuropsychological battery given that a large proportion of patients remain cognitively intact. As a 
result, several screening assessment tools have been developed for use in clinical (as well as research) 
settings. The aim of these screening tools is to detect cognitive and behavioural change in a briefer 
timescale. However, it is important to consider how well such measures have been validated and their 
likely clinical validity when diagnosing cognitive and behavioural impairment, especially according 
to the new Strong et al. (4) consensus criteria. The aim of this review was, therefore, to identify 
available ALS-specific screening tests for detecting cognitive and/or behavioural change and to assess 
their validity and diagnostic accuracy. 
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METHODOLOGY 
 
This systematic review was undertaken according to the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) standards (6). The main aim was to evaluate the validity of 
six ALS-specific screening tools referred to by Strong et al. (4).  Box 1 describes the screening tools 
in terms of who usually completes them and what they measure.  
 
Eligibility criteria  
The inclusion criteria included any original (observational) studies assessing validity of the screening 
tools against standardised batteries of neuropsychological function, questionnaires, current diagnostic 
criteria or recommended cut-offs from previous literature. No restriction was placed on the 
participants’ gender or age.    
 
Studies were excluded if they were not published in English or if the sample size was <30.  
 
Search strategy 
Papers were searched for in the MEDLINE, EMBASE, and PsycINFO databases. The databases were 
searched from their start-date until 4th week of June 2017, using the search format in Box 2.   
 
Study selection 
The titles and abstracts of all records in English identified by electronic search were screened for 
relevance. Most had no relevance to the search terms (Box 2) and some were conference abstracts. 
One study was excluded due to a cohort size of <30, leaving 14 studies to be included in the 
qualitative synthesis. A hand search was undertaken by examining reference lists of included studies; 
however, no additional records were identified.  
 
 
Risk of bias and methodology analysis 
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Risk of bias was evaluated on the basis of the following domains: patient selection and 
representativeness of the general ALS population, the blinding of the study (i.e. whether impairment 
on the cognitive or behavioural screening measure being validated was identified by the researchers 
independently of knowledge about impairment on other screening tools/diagnostic criteria against 
which it was being validated) and whether validation was undertaken against a gold standard 
neuropsychological battery, appropriate diagnostic criteria or  an accepted standardised ALS-specific 
screening tool. Blinding is essential to minimise expectation bias and a high degree of 
representativeness is important for the clinical relevance of the study data. Representativeness was 
judged by examining the sample size of ALS participants, their mean age and the percentage of males 
and females in each study. The rationale of rating allocation is detailed in Table 2. A study was 
classified as having a low risk of bias if it achieved a cumulative score of 4 or more on the above 
domains. A moderate risk of bias was defined as a score of 3 or 2 and a high risk of bias was defined 
as a score of 1 or 0.  
 
Data synthesis and extraction 
After selection, papers were examined carefully to extract data pertinent to the validity of the tools. 
Where available, measures extracted included specificity, sensitivity, positive predictive values 
(PPV), negative predictive values (NPV) and correlations. Cohort demographics were also extracted. 
Meta-analyses were not conducted due to study heterogeneity. 
 
RESULTS 
 
The electronic search yielded 180 studies after restricting studies to those in English and removing 
duplicates. Figure 1 shows the flow-chart of the search strategy as described above. After screening, 
14 eligible studies were included in a qualitative synthesis.  
 
 
Included studies 
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Table 1 presents the characteristics of the study cohorts in the 14 validation studies. Cohort sizes and 
disease duration varied considerably depending on sub-cohorts but all studies included a greater 
proportion of males than females. There was relatively little variation in years of education across 
studies. Some studies presented convergent validity in the form of correlations between the screening 
tools being investigated and well-validated equivalents. Control groups were used in most studies to 
provide normative data for cut-off scores.  
 
Methodology analysis and risk of bias 
Table 2 presents the risk of bias in the included studies. Bias estimates occasionally varied within 
studies depending on the type of validity being evaluated  
 
 
Validity data analysis 
 
Clinical validity data (see Table 3) 
 
Eight of the 10  studies assessing clinical validity had a low risk of bias (7–14) and two studies had a 
moderate risk of bias (15,16) (Table 2) for clinical validity data. Four studies (17–20) had both a 
moderate or low risk of bias (Table 2) as sensitivities/specificities were calculated for two different 
cohorts. Thus, no studies had a high risk of bias (Table 2), supporting their clinical validity.  
 
Clinical validity data for the ECAS 
 
Niven et al. (9) validated the ECAS at five different cut-offs for both the ECAS total score and the 
ALS-specific total score. Pinto-Grau et al. (7) proposed multiple cut-offs from normative data 
generating age-and education- adjusted norms. Both of these studies (7,9) reported moderate to high 
sensitivity and specificity values across multiple cut-off scores.  
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Lulé et al.(18) estimated sensitivity and specificity data for ECAS subdomains assessing memory, 
language, fluency and executive function in comparison to identical domains on the Consortium to 
Establish a Registry for Alzheimer’s Disease plus (CERAD plus) (21). Sensitivity was in the medium 
range across all subdomains and specificity was much higher for the executive function subdomain.  
 
In summary, ECAS sensitivity and specificity data presented here indicate high clinical validity. All 
studies (7,9,18) validated the ECAS against either a gold standard neuropsychological battery or the 
appropriate accepted diagnostic criteria. Further, all studies had an overall low risk of bias (Table 2) 
when assessing clinical validity; however, blinding was not reported in any of the studies and, 
therefore, this aspect of potential bias cannot be ruled out. The neuropsychological batteries used in 
two of these studies (7,9) assessed ALS-specific and ALS non-specific domains including fluency, 
language, memory, executive function and visuospatial function. However, Lulé et al. (18) validated 
the ECAS against the Alzheimer’s disease-specific CERAD plus (21) on only four domains with the 
omission of visuospatial function..  
 
Clinical validity data for the ALS-CBS 
Turon-Sans et al. (12) validated the ALS-CBS cognitive and behavioural sections independently for 
diagnosis of behavioural or cognitive impairment and for FTD. Across all of these cut-offs, 
sensitivity, specificity and NPV values were high but PPV showed considerable variation. Similar 
results were observed earlier by Woolley et al. (11) who had validated the ALS-CBS at different cut-
offs for cognitive and behavioural deficits and for FTD and by Branco et al. (10) who validated the 
ALS-CBS at a single cut-off to differentiate between ALS patients with and without executive 
impairment.  
 
The above data suggests that the ALS-CBS has high clinical validity. All studies had a low risk of 
bias (Table 2) with two studies blinding researchers (11,12) thereby reducing expectation bias. 
Moreover, all studies (10–12) validated the cognitive section of the ALS-CBS against a gold-standard 
neuropsychological battery using the original Strong et al. consensus criteria (5) to diagnose 
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impairment. Interestingly, the neuropsychological battery used by Branco et al. (10) also included 
domains used in the ECAS that evaluate visuospatial functions. Further, two studies (11,12) also 
validated the behavioural section of the ALS-CBS against these diagnostic criteria (5).  Woolley et al. 
(11) validated the ALS-CBS behavioural section against the Frontal Systems Behavior Scale (FrSBe) 
considering it to be the gold-standard; however, the FrSBe only assesses behaviour on the basis of 
three domains: apathy, disinhibition and executive dysfunction (22,23). Turon-Sans et al. (12) 
validated the behavioural section of the ALS-CBS against a wider range of tests assessing behavioural 
function, including the Frontal Behavioral Inventory (24), Neuropsychiatric Inventory (25) and 
Apathy Scale (26).  
 
Clinical validity data for the MiND-B  
Although the MiND-B has only been validated at two cut-off scores in two studies (13,14), calculated 
sensitivity and specificity values are high. Further, both of these studies (13,14) had a low risk of bias 
(Table 2) and validated the MiND-B against consensus criteria (5). Unfortunately, blinding was not 
reported. Mioshi et al. (14) validated two different cut-off scores (33 and 35) for the differentiation of 
ALS plus (cognitive or behavioural impairment) from ALS pure (only motor symptoms). A cut-off 
score of 35 was shown to have a higher sensitivity but lower specificity for detection of ALS plus in 
comparison to a cut-off score of 33, indicating that a cut-off of 35 increases the proportion of false 
positives (14). Patient cohorts in both studies (13,14) were subject to limited cognitive and 
behavioural assessment to aid diagnosis through the consensus criteria (5). As assessment was 
limited, patients may have been underdiagnosed prior to validation of the MiND-B, leading to a 
higher proportion of false positives (i.e. a lower specificity).  
 
 
Clinical validity data for the BBI  
Two studies validated the BBI at cut-off scores indicating mild behavioural change (>7) and at cut-off 
scores indicating severe behavioural change (>23). Both validation studies (8,17) present high 
sensitivity and specificity values at cut-off scores for both mild behavioural impairment and ALS-
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FTD. Pinto-Grau et al.’s (8) validation study had an overall low risk of bias (Table 2) and Elamin et 
al.’s original study (17) had an overall moderate/low risk of bias (Table 2). Like many of the 
validation studies evaluated here, blinding was not reported. In Elamin et al.’s (17) study, validation 
was carried out against the FrSBe (22). Additionally, a small cohort in this paper (17) were diagnosed 
with ALS-FTD using revised criteria (27). However, the study (17) itself highlighted a limitation in 
using the FrSBe (22) to validate the BBI; the FrSBe (22) does not consider the impact of motor 
impairment on behaviour (17). Therefore, Pinto-Grau et al. (8) cross-validated the BBI against the 
ALS-FTD-Q (20), both being ALS-specific measures that control for motor impairment, leading to 
validation data (8) that are more clinically applicable. Nonetheless, the BBI assesses a wider range of 
behavioural functions than the ALS-FTD-Q (20).  
 
Convergent validity  
Eleven studies presented correlation data as measures of convergent validity, correlating screening 
tools with other previously-validated screening tools assessing the same cognitive or behavioural 
function. The choice of measures against which to correlate the screening tools may be important in 
determining convergent validity; for example, the choice of a less ALS-specific measure 
incorporating fewer ALS-specific cognitive changes, such as the Mini Mental State Examination 
(MMSE), may have led to fewer high correlations being achieved. 
 
Pinto-Grau et al. (7) and Branco et al. (10) correlated the ECAS and the ALS-CBS respectively 
against subcomponents of a full neuropsychological battery. Pinto-Grau et al. (7) reported a 
correlation of 0.791 between the ECAS total score and all domains on the full battery. Branco et al. 
(10) reported correlation data that was statistically significant in six domains. Woolley et al. (11) also 
provided statistically significant correlation data concerning the behavioural aspect of the ALS-CBS.  
Three other studies correlated aspects of the ECAS score against other non-ALS-specific cognitive 
screening tests. Poletti et al. (16) reported the  correlation between ECAS total score and the Montreal 
Cognitive Assessment (MoCA) (28) and the Frontal Assessment Battery (FAB) (29) scores to be 
0.700 and 0.680 respectively. Ye et al. (15) found the ECAS total score to correlate with the MMSE 
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(30) (0.480) and FAB (29) (0.520). Finally, Lulé et al. (18) assessed concurrent validity between the 
ECAS total score and scores on the MoCA (28) and FAB (29). The correlation between MoCA (28) 
score and ECAS total score was 0.580 and between FAB (29) score and ECAS total score it was 
0.460.  It is not surprising that data presented in two of these studies (15,18) show the ECAS to have 
modest correlation with non-ALS-specific measures.   
 
Two studies (19,20) presented negative correlation coefficient scores between the ALS-FTD-Q and 
the FAB score (lower scores on the FAB are indicative of worse performance) and positive 
correlations between the ALS-FTD-Q and the Frontal Behavioral Inventory (FBI) (31) and Hospital 
Anxiety and Depression Scale (32) scores. Raaphorst et al. (20) reported the ALS-FTD-Q to have a 
lower correlation with the FAB (29) than with the FBI (24); the FBI (24) had a correlation of 0.79 
with the ALS-FTD-Q, suggesting high convergent validity (20). Watanabe et al. (19) presented data 
concerning discriminant validity. Here, the ALS-FTD-Q-J discriminated between ALS and ALS-
bvFTD patients, ALS and bvFTD patients and between ALS patients and controls. Raaphorst et al. 
(20) also demonstrated that the ALS-FTD-Q discriminated between ALS, ALS-bvFTD and controls. 
For both of these studies (19,20), discriminant validity was calculated against diagnoses made using 
either the Neary criteria (33) or the Rascovsky criteria (34), or both.  
 
Hsieh et al. (13) reported a significant  correlation (0.540) between MiND-B and the Mini-
Addenbrooke’s Cognitive Examination (M-ACE) (35) in an ALS-FTD cohort, showing behavioural 
impairment to correlate with cognitive impairment in ALS-FTD patients (13).    
 
Finally, two studies (8,17) correlated the BBI with other measures of behavioural change in ALS. 
Pinto-Grau et al. (8) reported a high correlation of 0.807 between the BBI total score and the ALS-
FTD-Q total score. This was expected as both screening tools are ALS-specific and cross-validation 
of the BBI against the ALS-FTD-Q revealed the BBI to have high clinical validity (Table 3) (8). In 
addition, Elamin et al. (17) showed the BBI to have moderate to high correlations with the domains of 
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apathy (0.727), disinhibition (0.638) and executive dysfunction (0.687) on the FrSBe (22). The same 
paper reported a medium size negative correlation of 0.442 between the BBI and the FAB (29).  
 
DISCUSSION 
 
This systematic review evaluated 14 papers. The majority of these papers presented validation data on 
the ALS-CBS and the ECAS, with some of the validation studies occurring as part of their translation 
into languages other than their original English (10,12,15,16,18,19) or as part of the development of 
more detailed norms (7)). The MiND-B, BBI and ALS-FTD-Q were validated in the remaining 
studies; this search detected no papers assessing the validity of the FBI-ALS.  
 
The papers detected by the search were of variable quality although, using our criteria, none were at 
risk of a high degree of bias. Generally, though, classification of impairment on the basis of the 
screening tool did not appear to have been undertaken blind to classification on the basis of the “gold 
standard” measure being used, although most studies did not report on this and, therefore, for the 
majority of studies (7–10,13–20) it was not possible to rule out the possibility of expectation bias. It is 
important to highlight, however, that in some studies (8,13,14,17,19,20) proxy responders may have 
been blind to diagnosis of behavioural change/ALS-FTD, even if researchers’ status was not reported 
by the study.  
 
While the samples were generally of a reasonable size and representative gender split, most studies 
did not justify their sample sizes, and these varied considerably. In some  studies (10,11,13,14) the 
participants’ demographics were only provided for study subcohorts. Furthermore, data concerning 
years of education were not provided consistently. In one study assessing concurrent validity (18) of 
the ECAS total score by comparing it with the FAB and MoCA tests, 9.3% of patients were unable to 
complete the MoCA and 5.1% were unable to complete the FAB due to physical impairment. This 
exclusion of a notable proportion of the cohort could be of further relevance when assessing study 
methodology. 
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Ten studies assessed clinical validity (7–14,17,18). For the ECAS, a screening tool that includes items 
measuring language and social cognition deficits, the reported sensitivity and specificity is high across 
all studies (7,9,18). The ECAS has also been shown to have high convergent validity (7,15,16,18). 
Moreover, the ECAS accommodates for motor and speech dysfunction by incorporating the verbal 
fluency index and offering completion in either a written or spoken format (4). Taking into 
consideration the new revised consensus criteria and the data presented in this systematic review, 
ECAS offers an attractive option for clinicians in need of a rapid, easy to administer screening tool.  
 
With regards to the ALS-CBS, clinical validity data is also promising, with high reported sensitivities 
and specificities (10–12). The ALS-CBS also accounts for motor dysfunction by allowing patients to 
answer questions using different means and is quicker to administer than the ECAS. However, the 
cognitive subscale of the ALS-CBS, which focuses on executive dysfunction, is somewhat limited in 
that it fails to assess domains of language and social cognition, now included aspects of cognitive 
impairment in the current consensus diagnostic criteria, and it is not yet known to what extent it may, 
therefore, underdiagnose cognitive impairment.  
 
The MiND-B displayed high clinical validity at two defined cut-offs (13,14). However, better clinical 
validity is likely to be achieved (13) when it is used concurrently with the Mini-ACE (35), a non-ALS 
specific screening test for cognitive change. Whilst validity data analysed here are promising (13,14), 
caution should be taken as the MiND-B assesses a limited set of behavioural functions and may miss 
manifestations of behavioural impairment mentioned in the Rascovsky criteria (34), used in the new 
consensus criteria (4) to guide the diagnosis of ALS with behavioural impairment and ALS-FTD. The 
ALS-FTD-Q has no studies assessing its clinical validity but two studies presented data concerning 
convergent validity (19,20). These studies display strong correlations between the ALS-FTD-Q and 
other measurement tools of behavioural change.   
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The BBI screens for behavioural change in ALS by assessing a large range of domains assessing 
frontal behaviours as described in the Neary criteria (33). The BBI assesses a wider spectrum of 
behavioural involvement in ALS than the ALS-FTD-Q and, therefore, may detect mild behavioural 
change in a more representative way (8). Further, the BBI takes into consideration the effects that 
motor dysfunction may have on behaviour. Validity data is scarce (8,17), however, and the field 
would  benefit from more studies assessing its validity in a larger population and at multiple age 
adjusted cut-offs.  
 
Motor impairment affecting speech or writing is often unaccounted for during routine 
neuropsychological testing and proves to be a confounding factor limiting patient performance. 
Where the screening tools were validated against a gold standard neuropsychological battery (7,9–
12,18), there remains some potential error in validation due to the gold standard neuropsychological 
measures not controlling adequately for motor slowing or speech impairment. Whilst it is likely that 
more recent validations (e.g. for the ECAS (9)) will have included such adjustments in their 
background neuropsychological assessments, this is not clear for all validation studies reported. It will 
be essential for future validation studies to take these potential limitations into account. The difficulty 
in choosing an inappropriate validation measure has been recognised in the use of the FrSBe when 
validating the behavioural subscale of the ALS-CBS (11) and the BBI (17) and it is important that 
cognitive and behavioural screening tool validations are undertaken against measures that do not 
unduly penalize patients’ performance due to motor and speech limitations.  
 
Taking into consideration the revised Strong et al. (4) consensus criteria and validation studies 
appraised here, the ECAS and ALS-CBS appear to offer clinical utility. It may be important to 
consider that the ECAS assesses a range of ALS-specific and non-specific cognitive functions while 
the ALS-CBS focuses more specifically on executive dysfunction. In particular, the ECAS allows for 
some detailed assessment of impairments in language and social cognition, two domains added to the 
most recent version of the consensus criteria. In terms of measuring behavioural change, the MiND-B 
and BBI have preliminary evidence of high clinical validity although the MiND-B has been used to 
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detect ALS-motor vs ALS-plus patients, with the latter classification incorporating patients with 
cognitive and/or behavioural changes; therefore, further work is needed to validate this measure in 
terms of its sensitivity and specificity with respect to behavioural change alone.  
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Box 1 Description of screening tools   
The Edinburgh Cognitive and Behavioural ALS Screen (ECAS)  (36) 
 
The ECAS is an assessment tool that can be administered by healthcare professionals other than neuropsychologists 
who have undergone appropriate training and completed by the patient at home visits or in the clinic environment. The 
ECAS can be answered by patients in a written manner or verbally, accounting for the presence of motor dysfunction. 
Questions assessing cognitive impairment and behavioural impairment are included in the screen. ALS-specific 
cognitive impairment is evaluated through the assessment of executive functions, social cognition, fluency and 
language. In addition, the ECAS assesses cognitive changes seen in non-ALS disorders, in the ALS non-specific section 
of the screening tool. The domains included here include memory and visuospatial function. Completion time is 
described to be in the order of 20 minutes. The ECAS requires the healthcare professional to assess behavioural change 
in the patient by interviewing a relative/carer. This supplementary assessment is based on the Rascovsky criteria (34) 
for diagnosis of behavioural-variant FTD. The cut-off score for the ECAS-Total Score is 105/136 and the cut-off score 
for the ALS-Specific Score is 77/100.  
 
The ALS Cognitive Behavioural Screen (ALS-CBS) (11) 
This screen is divided into a cognitive and behavioural section. The cognitive section is completed by the patient and 
there is a separate questionnaire to be completed by a healthcare professional or carer. The cognitive section, described 
as taking about 5 minutes to complete, assesses the domains of attention, concentration, mental tracking and monitoring 
and word initiation and retrieval (i.e., verbal fluency). The domains assessed in the behavioural section assessing 
alteration in behaviour over time include apathy, inhibition, emotional control, empathy, frustration tolerance, cognitive 
flexibility, insight, judgement, food preferences, language and decision-making. The language domain primarily 
highlights the presence of aphasia in the formation of neologisms or instances where the patient says the wrong word 
more often than usual. Answers can be gathered through the use of speech output devices, verbally or in writing. The 
ALS-CBS is scored out of 20; a score of ≤10 is indicative of probable FTD. A score of ≤16 suggests cognitive 
impairment (ALSci). The behavioural component of the ALS-CBS contains 15 items; the behavioural component is 
scored from 0-45; with a score of ≤32 accurately classifying ALS patients with FTD and a score ≤36 detecting more 
general behaviour impairment (ALSbi or ALS-FTD).  
 
The Motor Neurone Disease Behavioural Scale (MiND-B) (14) 
The MiND-B questionnaire quantifies behavioural changes in the person with ALS over the previous month in the 
following domains: disinhibition, apathy and stereotypical behaviour. It comprises nine items and is completed by one 
of the patient’s contacts. The cut-off scores for differentiating ALS from ALSci/ALSbi or FTD are 35/36 and 33/36 
respectively. These cut offs have varying reported sensitivities and specificities.  
 
The Frontal Behavioural Inventory - ALS (31) 
The Frontal Behavioural Inventory (FBI) is a 24- question survey completed by the caregiver that quantifies 
behavioural change in terms of apathy, indifference, disorganisation, inattention, personal neglect, aspontaneity, 
inflexibility, concreteness, loss of insight, logopenia, verbal apraxia and alien hand (24) Responses are scaled 
numerically: 0 (none/never), 1 (mild/occasional), 2 (moderate/often) and 3 (severe/most of the time). The newer ALS 
version of the FBI has extra questions that help clarify the behavioural symptoms specific to an FTD clinical picture 
(37).  
 
The ALS Frontotemporal Dementia Questionnaire (ALS-FTD-Q) (20) 
The ALS-FTD-Q is a 25-item questionnaire completed by the healthcare professional or caregiver and assesses 
behaviour change either over three years or describes behaviour in the previous month. These items include irritability, 
disinhibition, emotional lability, altered food preference, egocentricity, delusions (paranoia) and apathy; three items 
assessing memory, concentration and orientation in time are also included. The ALS-FTD-Q identifies patients with the 
behavioural variant of FTD (ALS-bvFTD). A score ≥22 was set as indicative of mild disturbances, and scores ≥29 were 
indicative of severe disturbances.  
 
The Beaumont Behavioural Inventory (BBI) (17)  
The BBI is a new screening tool for behavioural change in ALS, over two timeframes, i.e. “in the last 10 years” and 
“since the onset of MND”. It consists of 41 items and is a proxy-report behavioural assessment that takes around 5 to 
10 minutes to complete. It builds on other behavioural questionnaires by taking into consideration effects that motor 
dysfunction may have on behaviour. The BBI has items that assess a larger range of frontal behaviours described in the 
Neary criteria (33) and the revised bvFTD criteria (34). The range of frontal behaviours assessed includes aspects of 
apathy, behavioural disinhibition, social cognition deficits, perseverative, behavioural stereotypes or obsessive-
compulsive behaviours, dietary changes, utilisation behaviour, echolalia and altered response to sensory stimuli. The 
scale also includes 6 items examining cognitive changes representing frontotemporal change. A total BBI score ≥7 was 
indicative of behavioural abnormality; a score of 22.5 was held to indicate severe behavioural abnormality consistent 
with ALS-FTD.  
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Box 2 Search strategy used for searching MEDLINE, EMBASE and PsycINFO   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(((Edinburgh Cognitive and Behavioural ALS Screen) or (Edinburgh Cognitive and Behavioral ALS Screen) or 
(Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen) or (Edinburgh Cognitive and 
Behavioral Amyotrophic Lateral Sclerosis Screen) or Amyotrophic Lateral Sclerosis Cognitive Behavioural 
Screen or Amyotrophic Lateral Sclerosis Cognitive Behavioral Screen or ALS Cognitive Behavioural Screen or 
ALS Cognitive Behavioral Screen or ALS-CBS or Amyotrophic Lateral Sclerosis Frontotemporal Dementia 
Questionnaire or Amyotrophic Lateral Sclerosis Fronto-temporal Questionnaire or ALS-FTD-Q or Amyotrophic 
Lateral Sclerosis Fronto Temporal Dementia Questionnaire or Frontal Behavioural Inventory ALS Version or 
Frontal Behavioral Inventory ALS Version or Frontal Behavioural Inventory Amyotrophic Lateral Sclerosis 
Version or Frontal Behavioral Inventory Amyotrophic Lateral Sclerosis Version or The Motor Neurone Disease 
Behaviour Scale or The Motor Neuron Disease Behaviour Scale or The Motor Neurone Disease Behavior Scale 
or The Motor Neuron Disease Behavior Scale or MiND-B or BBI or Beaumont Behavioural Inventory or 
Beaumont Behavioral Inventory) and (valid* or specificit* or sensitivit* or accurac*)) 
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Table 1: Characteristics of the study cohorts in the validation studies 
 ECAS The Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen; ALS-CBS 
Amyotrophic Lateral Sclerosis Cognitive Behavioural Screen; ALS-FTD-Q Amyotrophic Lateral Sclerosis 
Frontotemporal Dementia Questionnaire; ALS-FTD-Q-J Amyotrophic Lateral Sclerosis Frontotemporal 
Dementia Questionnaire Japanese version; MiND-B The Motor Neuron Disease Behavioural Screen; BBI 
Study 
Screening 
test 
Cohort size 
[subcohorts] 
Age (mean) 
[subcohorts] 
Male sex (%) 
[subcohorts] 
Disease 
duration 
(months) 
[subcohorts] 
Years of 
education 
(mean) 
[subcohorts] 
 ECAS       
Pinto-Grau et 
al., 2017 (7) ECAS 30 59.83 63 n.r n.r 
Poletti et al., 
2016 (16) ECAS  107 62.98 65 21.07 10.81 
Lulé et al., 
2015 (18) ECAS 136 60 66.9 39 13.7 
Niven et al., 
2015 (9) ECAS 40 64.45 65 n.r 11.15 
Ye et al., 2016 
(15) ECAS 84 55.07 69 15.81 11.45 
 ALS-CBS      
Branco et al., 
2017 (10) ALS-CBS 
49 [ALSci (10) 
ALSni (39)] 
ALSci (55.10) 
ALSni (56.50) 
ALSci (60) 
ALSni (59) 
ALSci 
(25.80)ALSn
i (39.80)   
Woolley et al., 
2010 (11) ALS-CBS 
136 [ALS 
Cohort (105) 
ALS 
Validation 
(31)] 
ALS Cohort 
(58.6) ALS 
Validation 
(58.03) 
ALS Cohort 
(61) ALS 
Validation (55) 
ALS Cohort 
(34) ALS 
Validation 
(22) 
ALS Cohort 
(15.2) ALS 
Validation 
(14.5) 
Turon-Sans et 
al., 2016 (12) ALS-CBS 50 62.3 64 17.96 n.r 
 
ALS-
FTD-Q      
Watanabe et 
al., 2016 (19) 
ALS-
FTD-Q-J 98 67.7 59.2 21 n.r 
Raaphorst et 
al., 2012 (20) 
ALS-
FTD-Q 113 61.3 70.8 34 n.r 
 MiND-B      
Mioshi et al., 
2014 (14) MiND-B 
79  [Limb 
onset (55) 
Bulbar onset 
(24)] 
Limb onset 
(60.4) Bulbar 
onset (58.7) 
Limb onset (60) 
Bulbar onset 
(46) 
Limb onset 
(27.6) Bulbar 
onset (15.2) 
Limb onset 
(13.7) Bulbar 
onset (14.1) 
Hsieh et al., 
2016 (13) MiND-B 
70 [ALS-pure 
(27) ALS-plus 
(19) ALSFTD 
(24)] 
ALS-pure 
(56.3) ALS-
plus (57.6) 
ALSFTD 
(63.1) 
ALS-pure 
(59.3) ALS-
plus (63.2) 
ALSFTD (66.7) 
ALS-pure 
(18) 
ALS-plus 
(28.9) 
ALSFTD 
(40.1) 
ALS-pure 
(13.5) ALS-
plus (12.5) 
ALSFTD 
(12.3) 
 BBI      
Elamin et al., 
2017 (17) BBI 85 63.05 67.1 n.r 13.32 
Pinto-Grau et 
al., 2017 (8) BBI 
60 [ALS (55) 
ALS-FTD (5)] 
65.42 [ALS 
(65.18) ALS-
FTD (68.00) 
70 [ALS (69) 
ALS-FTD (80)] n.r 
13.3 [ALS 
(13.29) ALS-
FTD (12.20)] 
 18 
Beaumont Behavioural Inventory; ALSci Amyotrophic Lateral Sclerosis with cognitive impairment; ALSni 
Amyotrophic Lateral Sclerosis without executive impairment; ALS Cohort Amyotrophic Lateral Sclerosis 
patient cohort, ALS Validation Amyotrophic Lateral Sclerosis patient cohort used in validation section of 
study;  Limb onset Disease onset with clinical limb signs; Bulbar onset Disease onset with clinical bulbar 
signs; ALS-pure Amyotrophic Lateral Sclerosis with motor clinical features only; 
ALS-plus Amyotrophic Lateral Sclerosis with non-motor clinical features; ALSFTD Amyotrophic Lateral 
Sclerosis Frontotemporal Dementia; n.r Not recorded. 
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Table 2: Methodology Analysis 
 
Study  
Patient 
representativeness 
(0-2) 
Blinding  
(0-1) 
Validated against a gold 
standard 
neuropsychological 
battery/ 
diagnostic criteria (0-2) 
Risk of bias 
total score 
Risk of bias 
category 
ECAS 
Pinto-Grau et al., 
2017 (7) 2 
0  
n.r  2 4 Low 
Poletti et al., 2016 
(16) 2 
0  
n.r  1 3 Moderate 
Niven et al., 2015 
(9) 2 
0 
n.r 2 4 Low 
Lulé et al., 2015  
(18) 2  
0  
n.r  
1 (Concurrent validity)  
2 (Clinical validity) 3/4 Moderate/Low 
Ye et al., 2016 (15) 2 
0 
n.r 1 3 Moderate 
ALS-CBS 
Branco et al., 2017 
(10) 2 
0  
n.r 2 4 Low 
Woolley et al., 
2010 (11) 2 1 2 5 Low  
Turon-Sans et al., 
2016 (12) 2 1 2 5 Low 
MiND-B 
Hsieh et al., 2016 
(13) 2  
0  
n.r  2 4 Low  
Mioshi et al., 2014 
(14) 2 
0 
n.r 2 4 Low 
ALS-FTD-Q 
Watanabe et al., 
2016 (19) 2 
0  
n.r  
1 (2 for discriminant 
validity) 3/4 Moderate/Low 
Raaphorst et al., 
2012 (20) 2 
0 
n.r 
1 (2 for discriminant 
validity) 3/4 Moderate/Low 
BBI 
Elamin et al., 2017 
(17) 2 
0  
n.r  
1 (2 for ALS-FTD 
patients) 3/4 Moderate/Low 
Pinto-Grau et al., 
2017 (8) 2 
0  
n.r  2 4 Low 
 
Patient representativeness (0-2) 2 = highly representative cohort; 1= less representative cohort; 0 = 
unrepresentative cohort  
Blinding 1= blinded; 0= not blinded/blinding not reported n.r =not reported 
Validation against a gold standard neuropsychological battery (or diagnostic criteria for behavioural 
screens) 2= validation was against a gold standard neuropsychological battery (or diagnostic criteria for 
behavioural screens) or an accepted ALS-specific standardised measure; 1= validation against an accepted non-
ALS-specific standardised measure; 0=validation was not against a gold standard neuropsychological battery (or 
diagnostic criteria for behavioural screens) or other accepted ALS-specific or non-ALS-specific standardised 
measures.  
Two studies (13,14) were assigned a score of 2 in this category as they were validated against the 2009 Strong et 
al criteria; however, a limited number of tests were used to identify ALSci and it is not clear that measures were 
controlled for motor speed.  
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Table 3: Validation data: sensitivity, specificity, PPV, NPV and LR+ 
 
Study and reference 
groups used Screening test Sensitivity Specificity PPV NPV LR+ 
Pinto-Grau et al., 2017 (7) ECAS           
Controls were used to create 
age and education adjusted 
cut-off scores. Validation 
data was calculated at cut-
off scores for the diagnosis 
of cognitive impairment in 
an ALS cohort. 
Cutoff varies      
ECAS Total 1.000 0.800 0.375 1.000 n.r 
ECAS Specific 1.000 0.850 0.430 1.000 n.r 
ECAS Non-Specific  1.000 0.790 0.440 1.000 n.r 
Niven et al., 2015 (9) ECAS      
Controls were used to create 
population abnormality cut-
off scores. Validation data 
was calculated at cut-off 
scores for the diagnosis of 
cognitive impairment in an 
ALS cohort. 
ALS-Specific Score 
cut-off      
 ≤ 77 0.770 0.890 0.770 0.890 n.r 
 ≤ 78 0.850 0.810 0.690 0.920 n.r 
 ≤ 80 0.920 0.810 0.710 0.920 n.r 
 < 82 0.920 0.740 0.630 0.950 n.r 
 ≤ 83 1.000 0.740 0.650 1.000 n.r 
ECAS Total Score 
cut-off      
 ≤ 105 0.690 0.890 0.750 0.860 n.r 
 ≤ 107 0.770 0.810 0.670 0.880 n.r 
 ≤ 108 0.850 0.810 0.690 0.920 n.r 
 ≤ 110 0.920 0.810 0.710 0.960 n.r 
 ≤ 115 1.000 0.520 0.500 1.000 n.r 
Lulé et al., 2015 (18) 
ECAS      
Controls were used to 
generate cut-off scores. 
Validation data was 
calculated at cut-off scores 
for the diagnosis of 
cognitive impairment in an 
ALS cohort. 
ECAS Memory  0.330 0.920 n.r n.r n.r 
ECAS Language  0.330 0.750 n.r n.r n.r 
ECAS Fluency 0.500 0.910 n.r n.r n.r 
ECAS Executive 
Function 0.430 1.000 n.r n.r n.r 
Turon-Sans et al., 2016 
(12) ALS-CBS      
Validation was completed at 
optimal cut-off scores (for 
both the cognitive and 
behaviour sections) 
differentiating between ALS 
with no impairment and 
ALS with 
cognitive/behavioural 
impairment and between 
ALS with FTD and ALS 
without FTD. 
ALS-CBScog, cut-
off: 8 No FTD vs. 
FTD 0.833 0.750 0.313 0.971 n.r 
ALS-CBScog, cut-
off: 15 Normal vs. 
CI 0.862 0.620 0.758 0.765 n.r 
ALS-CBSbv, cut-
off: 35 No FTD vs. 
FTD 0.833 0.690 0.250 0.967 n.r 
ALS-CBSbv, cut-
off: 36 Normal vs. 
CI 0.933 0.743 0.610 0.963 n.r 
Branco et al., 2017 (10) ALS-CBS      
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A pre-determined cut-off 
score of 10 to differentiate 
between ALS with and 
without executive 
impairment was set. The 
study included controls 
matched by age, gender and 
education. 
Cutoff 10 ALS with 
executive 
impairment vs. ALS 
without executive 
impairment  0.900 0.872 n.r n.r n.r 
Woolley et al., 2010 (11) 
ALS-CBS      
 
 
Validation was completed at 
pre-determined cut-off 
scores considered optimal 
differentiating between ALS 
with cognitive impairment 
and ALS without cognitive 
impairment and between 
ALS with FTD and the 
remaining cohort (including 
ALS with no impairment, 
ALS with cognitive 
impairment, ALS with 
behavioural impairment, 
ALS with cognitive and 
behavioural impairment and 
healthy controls). 
Cognitive section      
Cut off 10 for FTD 1.000 1.000 1.000 1.000 n.r 
Cut off 17 for any 
cognitive deficit 0.850 0.860 0.690 0.710 n.r 
Behaviour section      
Cut off 32 for FTD 0.880 0.800 0.940 0.670 n.r 
Cut off 36 for any 
behavioural deficit 0.900 0.860 0.820 0.920 n.r 
Hsieh et al., 2016 (13) MiND-B      
Pre-determined 
recommended cut-off scores 
were used. Validation was 
completed at the 
recommended cut-off score 
of 33 differentiating ALS 
pure (only motor symptoms) 
from ALS plus (cognitive 
and behavioural symptoms).  Cutoff 33 0.900 0.790 0.730 0.780 4.320 
Mioshi et al., 2014 (14) 
MiND-B            
 
Cut-off scores were 
determined by discriminant 
analysis. Validation was 
completed cut-off scores of 
33 and 35 differentiating 
ALS pure (only motor 
symptoms) from ALS plus 
(cognitive and behavioural 
symptoms). 
  
Cutoff 35 0.900 0.500 0.778 0.727 n.r 
Cutoff 33 0.810 0.750 n.r n.r n.r 
Elamin et al., 2017 (17) 
BBI      
Validity data was calculated 
relative to the FrSBe, 
considering it to be the gold-
standard. Mild behavioural 
impairment cut-off scores 
Cutoff 7 0.879 0.789 0.725 0.911 n.r 
Cutoff 22.5 (for 
ALS-FTD) 0.900 0.960 0.750 0.987 n.r 
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were determined using data 
from controls. 
The cut-off score of 7 
identified mild behavioural 
change in an ALS cohort 
and the cut-off score of 22.5 
identified ALS-FTD in an 
ALS cohort.  
Pinto-Grau et al., 2017 (8) BBI      
Here, the BBI was cross-
validated against the ALS-
FTD-Q. The cut-off score of 
7 identified mild behavioural 
change the cut-off score of 
23 indicated severe 
behavioural change in an 
ALS cohort.   
Cutoff 7 0.500 0.760 n.r n.r n.r 
Cutoff 23 1.000 0.920 n.r n.r n.r 
ECAS The Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen; ALS-CBS 
Amyotrophic Lateral Sclerosis Cognitive Behavioural Screen; ALS-FTD-Q Amyotrophic Lateral Sclerosis 
Frontotemporal Dementia Questionnaire; MiND-B The Motor Neuron Disease Behavioural Screen; BBI 
Beaumont Behavioural Inventory; FrSBe Frontal Systems Behavior Scale; PPV Positive predictive value; NPV 
Negative predictive value; LR+ Likelihood ratio (sensitivity/1-specificity); ALS-CBScog Cognitive section of 
ALS-CBS; ALS-CBSbv Behavioural section of ALS-CBS; ALS-FTD Amyotrophic Lateral Sclerosis 
Frontotemporal Dementia; FTD Frontotemporal dementia; CI Cognitive impairment; n.r Not recorded 
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Figure 1. PRISMA Flow-Diagram for Search Strategy (http://www.prisma-
statement.org/PRISMAStatement/Checklist.aspx)  
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